Pfizer Inc. (NYSE:PFE) Announces $0.43 Quarterly Dividend

Pfizer Inc. (NYSE:PFE) announced a quarterly dividend on Friday, December 12th. Shareholders of record on Friday, January 23rd will be paid a dividend of 0.43 per share by the biopharmaceutical company on Friday, March 6th. This represents a c) annualized dividend and a yield of 6.7%. The ex-dividend date is Friday, January 23rd.

Pfizer has increased its dividend payment by an average of 0.0%annually over the last three years and has increased its dividend every year for the last 16 years. Pfizer has a dividend payout ratio of 55.8% meaning its dividend is sufficiently covered by earnings. Analysts expect Pfizer to earn $3.03 per share next year, which means the company should continue to be able to cover its $1.72 annual dividend with an expected future payout ratio of 56.8%.

Pfizer Stock Performance

NYSE:PFE opened at $25.52 on Wednesday. The company has a market capitalization of $145.07 billion, a price-to-earnings ratio of 14.83 and a beta of 0.47. The business has a 50 day moving average of $25.38 and a 200 day moving average of $24.99. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. Pfizer has a 1-year low of $20.92 and a 1-year high of $27.69.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The firm had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, sell-side analysts predict that Pfizer will post 2.95 earnings per share for the current fiscal year.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer signed a licensing deal to use Novavax’s Matrix‑M adjuvant for vaccine development, which could expand Pfizer’s vaccine capabilities without heavy internal R&D spend and supports future product launches. Novavax enters license agreement with Pfizer for vaccine development
• Positive Sentiment: Investor outlets highlighted Pfizer as a dividend buy, boosting the income case for long‑term holders and attracting yield‑focused demand. This supports a case for defensive inflows even amid growth concerns. 3 No-Brainer Dividend Stocks to Buy Right Now — Including Pfizer
• Neutral Sentiment: Analysts and outlets are reassessing Pfizer’s valuation and shareholder return profile as revenue mix shifts (lower COVID sales versus steady core drugs); this is prompting rotation rather than a clear buy/sell signal. Pfizer (PFE) Valuation Check As Investors Reassess Recent Shareholder Returns
• Neutral Sentiment: Q4 outlook commentary centers on growth from Eliquis and softer COVID‑19 sales; investors will watch earnings for confirmation of non‑oncology stability. What to Expect From Pfizer’s Non‑Oncology Business in Q4?
• Negative Sentiment: Industry execs at the JPMorgan Healthcare Conference flagged drug‑pricing pressure, looming patent cliffs and intense dealmaking — themes that weigh on growth visibility for big pharma, including Pfizer. Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
• Negative Sentiment: Pfizer is exiting its ~11.7% stake in HIV‑focused ViiV Healthcare as Shionogi boosts its holding; the exit reduces Pfizer’s exposure to that growth area and signals a portfolio reshuffle that could concern some investors. Japan’s Shionogi boosts ViiV stake to 21.7% as Pfizer exits
• Negative Sentiment: CEO Albert Bourla said U.S. drug prices are coming down, reinforcing investor concerns about margin pressure from policy and pricing trends. Pfizer CEO Albert Bourla: U.S. drug prices are coming down

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.